Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses a phase III randomized trial that compared the two new agents nab-paclitaxel (Abraxane) and ixabepilone (Ixempra) to the standard weekly agent paclitaxel (Taxol) for patients with locally advanced or metastatic breast cancer.
For more on this study, visit [ Ссылка ]
